Table 1

FITC-insulin treatment (40-50 µg/kg)	Route of administration	Dose regimen	*Averaged fluorescence level (pdu)**
Microemulsion	Intranasal	1x1d	86.3±36.1 (n=13) S1, S2
Aqueous solution	Intranasal	1x1d	51.4±13.2 (n=13)
Aqueous solution	IV	1x1d	49. 6±10.1 (n=14)
Microemulsion	Intranasal	2x1d	138.5±80. 6 (n=10) S1, S2
Aqueous solution	Intranasal	2x1d	48.7±5.5 (n=14)
Aqueous solution	IV	2x1d	46.0±8.5 (n=11)
Microemulsion	Intranasal	3x1d	65.7±17.3 (n=13) S1
Aqueous solution	Intranasal	3x1d	36.4±4.5 (n=15) S2
Aqueous solution	IV	3x1d	62.3±20.6 (n=13) S1
Microemulsion	Intranasal	1x1d for 5d	109.4±45.5 (n=15) S1
Aqueous solution	Intranasal	1x1d for 5d	51.6±7.1 (n=31)

*pdu is the abbreviation for ‘procedure defined unit’

Table 1: Determination of fluorescence levels in brain tissue slices using MATLAB image processing. Statistically significant difference (ANOVA, p<0.01) compared with data obtained after administrations at the same dose regimen of nasal aqueous solutionS1 and IV aqueous solutionS².
1x1d = 24 hours after 1 application;
2x1d = 24 hours after 2 applications at t=0 and 12h;
3x1d = 24 hours after 3 applications at t=0, 8h, and 16h;
1x1d for 5d= at day 5 after 5 daily applications.